Rachel A. Chiaverelli

Director, Translational Sciences Oncology Strategy Lead at Daiichi Sankyo

Rachel A. Chiaverelli has a diverse work experience in the fields of translational medicine, clinical biomarker development, medical affairs, scientific business development, and research. Rachel A. is currently serving as the Director of Translational Sciences Oncology Strategy Lead at Daiichi Sankyo, Inc. Rachel A. previously held positions such as Adjunct Assistant Professor at Temple University, Senior Director of Translational Medicine/Clinical Biomarker Lead at Prelude Therapeutics, and Director of Medical Affairs/Scientific Business Development and Clinical Operations at Champions Oncology, Inc. Rachel A. has also worked as a Medical Science Liaison at The Angiogenesis Foundation and GlaxoSmithKline, and as a Doctoral Candidate at the USDA Jean Mayer Human Nutrition Research Center on Aging. Rachel's research experience includes investigating the effects of cigarette smoke on lung disease development and progression, utilizing assays such as western blot, RT-PCR, ELISA, and HPLC.

Rachel A. Chiaverelli holds a Bachelor of Science (B.S.) degree in Biology, General from Temple University. Rachel A. also holds a Master of Science (M.S.) degree in Biotechnology from Temple University. Additionally, Rachel has pursued a Doctor of Philosophy (Ph.D.) in Biochemical and Molecular Nutrition from Tufts University School of Medicine. The specific start and end years for each degree are not provided.

Links

Previous companies

Champions Oncology logo
Prelude Therapeutics logo

Timeline

  • Director, Translational Sciences Oncology Strategy Lead

    December, 2022 - present